P. J. Johnson

发表

Fucosyltransferases: Differential plasma and tissue alterations in hepatocellular carcinoma and cirrhosis

M. Du, W. Hutchinson, Roger Williams, 1991, Hepatology.

Impaired binding properties of thyroxine‐binding globulin in hepatocellular carcinoma and chronic liver disease

R. Williams, P. Johnson, W. Hutchinson, 1991, Hepatology.

Plasma carcinoembryonic antigen in the diagnosis and management of patients with hepatocellular carcinoma

P. Johnson, S. Carter, R. Williams, 1981, Cancer.

Hepatitis B envelope protein mutants in human hepatocellular carcinoma tissues

J. Tam, S. Zhong, P. Johnson, 1999, Journal of viral hepatitis.

New treatment for hepatocellular carcinoma

P. Johnson, P. J. Johnson, 1998, Journal of gastroenterology and hepatology.

Serum ferritin in hepatocellular carcinoma. A comparison with alphafetoprotein

P. Johnson, R. Williams, S. Bullock, 1983, Cancer.

The control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy

R. Williams, B. Greenway, M. Iqbal, 1982, The British journal of surgery.

Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high‐incidence and low‐incidence areas

S. Zaman, P. Johnson, Roger Williams, 1990, Cancer.

Control of malignant ascites with spironolactone

Roger Williams, R. Williams, B. Greenway, 1982, The British journal of surgery.

Induction of remission in hepatocellular carcinoma: A comparison of VP 16 with adriamycin

Roger Williams, P. Johnson, W. Melia, 1983, Cancer.

‘Potentially curative therapies’ for hepatocellular carcinoma: how many patients can actually be cured?

P. Lai, A. Cucchetti, G. Ercolani, 2023, British Journal of Cancer.

A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report.

L. Hunt, P. Johnson, N. Haboubi, 1987, Journal of hepatology.

Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications.

S. Leung, P. Johnson, A. Chan, 2000, International journal of radiation oncology, biology, physics.

Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy.

P. Johnson, A. Chan, P. Teo, 1999, International journal of radiation oncology, biology, physics.

Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

D. Vergani, R. Williams, P. Johnson, 1990, The Lancet.

The Natural Course and Heterogeneity of Autoimmune-Type Chronic Active Hepatitis

A. Eddleston, A. Eddleston, P. Johnson, 1991, Seminars in liver disease.

Azathioprine for long-term maintenance of remission in autoimmune hepatitis.

R. Williams, P. Johnson, I. Mcfarlane, 1995, The New England journal of medicine.

A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin

D. Stocken, P. Johnson, J. Buckels, 2007, Annals of Surgical Oncology.

Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population.

Masatoshi Kudo, Philip J. Johnson, M. Kudo, 2012 .

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

K. Tashima, D. Skiest, J. Stanford, 1999, The New England journal of medicine.

Sex-steroid enzymes, aromatase and 5 alpha-reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue.

P. Johnson, M. Wilkinson, R. Williams, 1983, Clinical science.

Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres.

A. Li, R. Ho, P. Johnson, 1998, International journal of radiation oncology, biology, physics.

HLA class II alleles in Chinese patients with hepatocellular carcinoma.

P. Donaldson, P. Johnson, S. Ho, 2001, Liver.

INDUCTION OF REMISSION IN HEPATOCELLULAR CARCINOMA WITH DOXORUBICIN

Roger Williams, Roger Williams, I. Murray-Lyon, 1978, The Lancet.

Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin.

A. Li, P. Johnson, K. W. Chan, 1997, The British journal of radiology.

Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol.

N. Dobbs, Roger Williams, P. Harper, 1991, Journal of hepatology.

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen

J. Neoptolemos, J. Neoptolemos, P. Johnson, 1999, British Journal of Cancer.

Ultrasonography in surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease

D. Cuthbertson, O. Elshaarawy, D. Palmer, 2023, Hepatoma Research.

New treatment for hepatocellular carcinoma

P. J. Johnson, 1998, Journal of gastroenterology and hepatology.

Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin.

P. Johnson, E. Metivier, R. Williams, 1990, Journal of hepatology.

Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis.

Roger Williams, R. Williams, P. Johnson, 1997, Journal of hepatology.

Excellent prognosis in wilsonian chronic active hepatitis: New data or an article of faith?

Roger Williams, P. J. Johnson, 1991, Hepatology.

Arteriovenous shunts in patients with hepatic tumors.

A. Li, P. Johnson, S. Ho, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.